Hermetica Superfood Encyclopedia
The Short Answer
Iron sucrose delivers elemental iron as a ferric oxyhydroxide-sucrose complex that dissociates in vivo, enabling transferrin-mediated transport to erythroid precursor cells for hemoglobin synthesis. In chronic kidney disease patients with iron deficiency anemia, intravenous administration produces near-complete bioavailability with peak serum iron levels averaging 30 mg/L within 10 minutes, significantly raising ferritin and reducing total iron-binding capacity within four weeks.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordiron sucrose
Iron Sucrose — botanical close-up
Health Benefits
**Iron Deficiency Anemia Correction**
Iron sucrose replenishes depleted iron stores by delivering elemental iron directly into circulation, bypassing gastrointestinal absorption limitations and rapidly normalizing serum iron and ferritin levels in deficient patients.
**Hemoglobin Synthesis Support**
Released ferric iron is incorporated into hemoglobin within developing erythroid precursor cells in the bone marrow, restoring red blood cell oxygen-carrying capacity in patients unable to absorb adequate oral iron.
**Reduction of Total Iron-Binding Capacity (TIBC)**
Intravenous iron repletion saturates available transferrin binding sites, measurably reducing TIBC within weeks, which serves as a pharmacodynamic marker of successful iron store replenishment.
**Improved Outcomes in CKD Patients on Dialysis**
Hemodialysis patients experience chronic iron losses through the dialysis circuit; iron sucrose replenishes these losses efficiently, supporting erythropoiesis-stimulating agent (ESA) efficacy and reducing required ESA doses.
**Favorable Safety Profile Versus Iron Dextran**
Iron sucrose is associated with a lower incidence of severe anaphylactic reactions compared to high-molecular-weight iron dextran, making it a preferred parenteral iron option in clinical guidelines for CKD-related anemia.
**Support for Non-Dialysis CKD Anemia**
Patients with CKD not yet on dialysis who cannot tolerate or absorb oral iron benefit from periodic iron sucrose infusions to maintain adequate iron stores for endogenous erythropoiesis.
**Perioperative Anemia Management**
In select surgical and obstetric contexts, iron sucrose is used off-label to rapidly restore iron stores preoperatively or postpartum when oral iron is insufficient or contraindicated.
Origin & History
Natural habitat
Iron sucrose is a synthetic pharmaceutical compound, not derived from a natural geographic or botanical source. It is manufactured through the controlled complexation of ferric oxyhydroxide with sucrose under sterile industrial conditions to produce a stable colloidal solution. First developed in Europe and later approved by the U.S. FDA in 2000, it has no agricultural cultivation or wild-harvesting history.
“Iron sucrose has no history in traditional or folk medicine systems, as it is an entirely modern pharmaceutical entity first synthesized and commercialized in the latter half of the 20th century. The broader therapeutic use of intravenous iron dates to the mid-20th century when iron dextran was introduced for patients unable to absorb oral iron; iron sucrose emerged as a safer alternative developed largely in European clinical settings before receiving U.S. FDA approval in November 2000 under the brand name Venofer. Its development reflected advancing understanding of iron metabolism in chronic kidney disease and the limitations of oral iron therapy in patients with uremia and gastrointestinal dysfunction. There are no traditional preparation methods, indigenous uses, or cultural healing traditions associated with iron sucrose, as its existence is entirely defined by modern pharmaceutical chemistry and nephrology practice.”Traditional Medicine
Scientific Research
Iron sucrose has been evaluated in multiple prospective clinical trials and comparative studies, predominantly in chronic kidney disease populations, including both hemodialysis-dependent and non-dialysis CKD patients, with evidence quality categorized as moderate-to-strong for its approved indications. Pharmacodynamic studies consistently demonstrate significant increases in serum ferritin and transferrin saturation (TSAT) alongside reductions in TIBC within four weeks of treatment initiation, serving as validated surrogate endpoints for iron store repletion. Comparative trials have established non-inferiority or superiority to oral iron and a more favorable safety profile versus high-molecular-weight iron dextran, though head-to-head data against newer agents such as ferric carboxymaltose are more limited in scope. The totality of evidence supports its clinical utility in CKD-associated iron deficiency anemia, but large-scale randomized controlled trials with hard cardiovascular or mortality endpoints are less robust than surrogate-marker data.
Preparation & Dosage
Traditional preparation
**Injectable Solution (Standard)**
20 mg elemental iron per mL; the most common presentation is 200 mg/10 mL (Venofer) for single-dose administration
Available as .
**Intravenous Injection**
200 mg elemental iron administered as a slow IV push over 2–5 minutes per session; may be repeated as clinically indicated
**Intravenous Infusion**
200–400 mg diluted in normal saline infused over 15 minutes to 4 hours depending on dose and clinical protocol
**Hemodialysis Patients**
100–200 mg per dialysis session, with a cumulative repletion target of approximately 1,000 mg iron over 10 sessions
Typical replacement regimen involves .
**Non-Dialysis CKD Patients**
200–300 mg repeated at defined intervals based on ongoing monitoring of ferritin and transferrin saturation targets
Doses of .
**Dose Individualization**
500 mg)
Total iron deficit calculated using Ganzoni formula (Total iron deficit [mg] = body weight [kg] × [target Hb − actual Hb g/dL] × 2.4 + iron stores .
**Administration Setting**
Must be administered in a clinical setting with monitoring for at least 30 minutes post-infusion due to risk of hypersensitivity reactions; not suitable for home or self-administration.
Nutritional Profile
Iron sucrose provides elemental iron as its sole nutritionally relevant component, at a concentration of 20 mg elemental iron per mL of solution. Each standard 10 mL vial delivers 200 mg of elemental iron in the ferric (Fe³⁺) state complexed with sucrose (a disaccharide of glucose and fructose). The sucrose component contributes negligible caloric value in clinical doses and is 68–75% renally excreted within 24 hours; it does not contribute meaningfully to dietary carbohydrate intake. No vitamins, amino acids, or other micronutrients are present. Bioavailability of iron from iron sucrose via the intravenous route is essentially 100%, in stark contrast to oral ferrous salts which typically achieve 10–20% gastrointestinal absorption under optimal conditions.
How It Works
Mechanism of Action
Following intravenous injection, iron sucrose is taken up by the reticuloendothelial system, where the ferric oxyhydroxide-sucrose complex dissociates, releasing free ferric iron into plasma. The released iron binds to transferrin (the primary iron transport protein), forming the transferrin-iron complex that is recognized by transferrin receptor 1 (TfR1) on erythroid precursor cells in the bone marrow. Receptor-mediated endocytosis internalizes the complex, and iron is released into the cytoplasm at endosomal pH for incorporation into protoporphyrin IX to form heme, and subsequently into hemoglobin tetramers during red blood cell maturation. Excess iron is stored intracellularly as ferritin or hemosiderin in hepatocytes and macrophages of the reticuloendothelial system, replenishing the total body iron depot and reducing compensatory upregulation of hepcidin-suppressive signaling associated with iron deficiency.
Clinical Evidence
Clinical studies of iron sucrose have focused primarily on chronic kidney disease patients, with pharmacodynamic endpoints including serum ferritin, transferrin saturation, hemoglobin concentration, and TIBC as primary outcomes. In hemodialysis patients, cumulative doses of 1,000 mg iron sucrose administered over multiple sessions have been shown to restore transferrin saturation and ferritin to target ranges, with hemoglobin improvements typically observed over 4–8 weeks in conjunction with erythropoiesis-stimulating agents. Studies comparing iron sucrose to oral ferrous sulfate in non-dialysis CKD patients have demonstrated superior iron store repletion with parenteral iron, particularly in patients with gastrointestinal intolerance or malabsorption. Overall confidence in efficacy for its approved indications is high based on consistent pharmacodynamic data, though long-term hard-outcome RCTs (mortality, cardiovascular events) remain limited.
Safety & Interactions
Common adverse effects occurring in clinical use include nausea, vomiting, diarrhea, hypotension, pruritus, arthralgia, myalgia, headache, dizziness, constipation, muscle cramps, injection site reactions, dysgeusia, and low-grade fever; most are transient and mild-to-moderate in severity. Serious hypersensitivity reactions—including anaphylaxis, angioedema, bronchospasm, chest discomfort, and cardiovascular collapse—are rare but potentially life-threatening, necessitating post-administration monitoring for a minimum of 30 minutes in a setting equipped for resuscitation. Drug interactions include reduced bioavailability of oral bisphosphonates (e.g., alendronate) and aluminum-containing antacids when co-administered; aspirin serum concentrations may be modestly reduced. Iron sucrose is contraindicated in patients with non-iron-deficiency anemias, iron overload states (e.g., hemochromatosis, hemosiderosis), and known hypersensitivity to iron sucrose or any component; use in pregnancy (Category B) and lactation requires individualized risk-benefit assessment, and geriatric patients may require dose modifications based on hepatic, renal, and cardiac function.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Iron saccharateSucroferric oxyhydroxideFerric oxyhydroxide sucrose complexVenoferIron(III) hydroxide sucrose
Frequently Asked Questions
What is iron sucrose used for?
Iron sucrose is used intravenously to treat iron deficiency anemia, most commonly in patients with chronic kidney disease (CKD), including those on hemodialysis or peritoneal dialysis. It replenishes iron stores when oral iron is ineffective, poorly tolerated, or insufficient to meet elevated iron demands, and is also used in some non-CKD clinical contexts such as postpartum anemia or pre-surgical optimization.
How is iron sucrose administered and what is the typical dose?
Iron sucrose is administered exclusively by intravenous injection or infusion in a clinical setting; it cannot be taken orally. A common dose is 200 mg of elemental iron per session, given as a slow IV push over 2–5 minutes or diluted in saline and infused over 15 minutes to several hours, with total cumulative doses and frequency individualized based on calculated iron deficit, hemoglobin targets, and ferritin/transferrin saturation monitoring.
What are the side effects of iron sucrose?
Common side effects include nausea, vomiting, diarrhea, headache, dizziness, low blood pressure, joint and muscle pain, itching, constipation, muscle cramps, injection site reactions, and altered taste. Serious but rare reactions include anaphylaxis, angioedema, difficulty breathing, irregular heartbeat, and loss of consciousness, which is why patients are monitored for at least 30 minutes after each dose in a medically supervised environment.
How quickly does iron sucrose work?
Peak serum iron levels occur approximately 10 minutes after intravenous injection, reflecting near-immediate bioavailability via the IV route. Clinically meaningful improvements in ferritin and transferrin saturation are typically observed within two to four weeks of initiating treatment, while hemoglobin increases, particularly when combined with erythropoiesis-stimulating agents, generally become apparent over four to eight weeks.
Is iron sucrose safe during pregnancy?
Iron sucrose is classified as FDA Pregnancy Category B, meaning animal studies have not demonstrated fetal harm but adequate well-controlled human studies are lacking. It may be used during the second and third trimesters when the benefits outweigh potential risks and oral iron is insufficient; use in the first trimester is generally avoided. Prescribing decisions during pregnancy require individualized clinical judgment balancing maternal anemia severity against theoretical fetal risk.
Does iron sucrose interact with common medications?
Iron sucrose may interact with certain medications including ACE inhibitors, which can potentiate hypotensive effects, and some antibiotics like tetracyclines, which may compete for iron binding. It's important to inform your healthcare provider about all medications you're taking before receiving iron sucrose infusions. Your doctor can adjust timing or dosing to minimize potential interactions.
Who benefits most from iron sucrose supplementation?
Iron sucrose is most beneficial for patients with iron deficiency anemia who cannot tolerate oral iron supplements due to gastrointestinal side effects, have severe malabsorption, or require rapid iron repletion such as those undergoing dialysis or with chronic kidney disease. It's particularly valuable for patients with inflammatory bowel disease or those who need iron restoration before surgery. Your healthcare provider can determine if iron sucrose is appropriate for your specific condition.
How does iron sucrose compare to other forms of iron supplementation?
Iron sucrose is a parenteral (intravenous) form that bypasses gastrointestinal absorption issues, making it more effective than oral iron for patients with malabsorption or severe GI sensitivity. Unlike ferrous sulfate or other oral preparations, iron sucrose delivers iron directly into circulation and typically shows faster results in correcting anemia. However, it requires clinical administration and monitoring, whereas oral forms can be self-administered at home.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w iron-sucrose curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
